查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510458

丙型肝炎市场 - 全球产业规模、份额、趋势、机会和预测，按类型、治疗、诊断、给药途径、配销通路、地区和竞争细分，2019-2029F

Hepatitis C Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Diagnosis, By Route of Administration, By Distribution Channel, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年全球丙型肝炎市场估值为81.2 亿美元，预计在预测期内将稳定成长，到2029 年复合年增长率为5.25%。健康问题。全球丙型肝炎市场充满活力，其特点是治疗、诊断技术的进步和对该疾病的认识不断增强。近年来，C型肝炎市场发生了重大转变，重点是提高治疗效果、减少副作用和扩大护理范围。製药业的主要参与者正在积极从事研究和开发，以将创新疗法推向市场。

市场概况
预测期 2025-2029
2023 年市场规模 81.2亿美元
2029 年市场规模 109.9亿美元
2024-2029 年复合年增长率 5. 25%
成长最快的细分市场 慢性C型肝炎
最大的市场 北美洲

直接作用抗病毒药物 (DAA) 的推出彻底改变了丙型肝炎的治疗，以更短的治疗时间提供更高的治癒率。这些药物针对丙型肝炎病毒生命週期中的特定步骤，最大限度地减少副作用并改善整体治疗结果。市场不断见证新的、更有效的 DAA 的推出，为患者提供更好的选择，为医疗保健提供者提供增强的工具来对抗这种疾病。丙型肝炎在全球范围内流行，某些地区比其他地区面临更高的负担。努力提高认识、筛检和诊断对于早期介入和治疗至关重要。公共卫生运动和措施有助于提高意识，减少与疾病相关的耻辱，并促进广泛的检测。

主要市场驱动因素

盛行率和意识的提高正在推动全球丙型肝炎市场

政府措施和医疗保健政策正在推动全球丙型肝炎市场

主要市场挑战

诊断和护理相关的挑战

治疗费用

主要市场趋势

技术进步

细分市场洞察

类型洞察

治疗见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球丙型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依类型（急性C型肝炎、慢性C型肝炎、其他）
    • 依治疗（抗病毒药物、疫苗、免疫调节药物、手术、其他）
    • 按诊断（肝臟切片、血液检查、影像学检查等）
    • 依给药途径（口服、肠胃外、其他）
    • 按配销通路（医院药房、零售药房、网路药房、其他）
    • 按公司划分 (2023)
    • 按地区
  • 市场地图

第 6 章：北美丙型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按治疗
    • 透过诊断
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲丙型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按治疗
    • 透过诊断
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区丙型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按治疗
    • 透过诊断
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲丙型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按治疗
    • 透过诊断
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲C型肝炎市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按类型
    • 按治疗
    • 透过诊断
    • 依给药途径
    • 按配销通路
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim International GmbH
  • Bayer AG
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche AG
  • Bristol-Myers Squibb Company

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 23902

Global Hepatitis C Market was valued at USD 8.12 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Hepatitis C, a viral infection affecting the liver, has emerged as a significant global health concern. The global hepatitis C market is a dynamic landscape marked by advancements in treatment, diagnostic technologies, and a growing awareness of the disease. The hepatitis C market has undergone substantial transformation in recent years, with a focus on improving treatment efficacy, reducing side effects, and expanding access to care. Key players in the pharmaceutical industry are actively engaged in research and development to bring innovative therapies to market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 8.12 Billion
Market Size 2029USD 10.99 Billion
CAGR 2024-20295. 25%
Fastest Growing SegmentChronic Hepatitis C
Largest MarketNorth America

The introduction of direct-acting antivirals (DAAs) has revolutionized hepatitis C treatment, offering higher cure rates with shorter treatment durations. These drugs target specific steps in the HCV life cycle, minimizing side effects and improving overall treatment outcomes. The market continues to witness the launch of new and more potent DAAs, providing patients with better options and healthcare providers with enhanced tools to combat the disease. Hepatitis C has a global prevalence, with certain regions facing higher burdens than others. Efforts to increase awareness, screening, and diagnosis are crucial for early intervention and treatment. Public health campaigns and initiatives are contributing to heightened awareness, reducing the stigma associated with the disease, and promoting widespread testing.

Key Market Drivers

Rising Prevalence and Awareness is Driving the Global Hepatitis C Market

Hepatitis C, a viral infection affecting the liver, has become a significant global health concern, prompting increased attention from healthcare professionals, policymakers, and the pharmaceutical industry. The rising prevalence of hepatitis C, coupled with a growing awareness of the disease, is driving the global hepatitis C market. The World Health Organization (WHO) estimates that over 70 million people worldwide are infected with the hepatitis C virus (HCV). The majority of these individuals are unaware of their infection, leading to the continued transmission of the virus. The prevalence is particularly high in certain regions, such as Asia and Africa, where access to healthcare resources may be limited.

Efforts to raise awareness about hepatitis C and its consequences have been instrumental in driving early detection and treatment. Global campaigns, educational programs, and initiatives by healthcare organizations have contributed to increased public awareness, leading to more individuals seeking testing and treatment options. Technological advancements in diagnostic tools have played a crucial role in the early detection of hepatitis C. Improved testing methods allow for quicker and more accurate diagnosis, enabling healthcare providers to identify and treat infected individuals promptly. This has contributed to the overall reduction in the transmission of the virus. The pharmaceutical industry has responded to the rising prevalence of hepatitis C by investing in the research and development of innovative therapies. Direct-acting antivirals (DAAs) have emerged as a breakthrough in hepatitis C treatment, offering high cure rates with fewer side effects compared to traditional treatments. The availability of effective and well-tolerated medications has significantly improved the prognosis for individuals living with hepatitis C.

Governments worldwide are recognizing the impact of hepatitis C on public health and are implementing various measures to combat the disease. National screening programs, subsidies for antiviral medications, and awareness campaigns are being rolled out to address the challenges posed by hepatitis C. Despite the progress made, challenges such as limited access to healthcare in certain regions, high treatment costs, and stigma associated with the disease remain. However, these challenges also present opportunities for collaboration between governments, non-profit organizations, and pharmaceutical companies to develop sustainable solutions and ensure equitable access to treatment. The global hepatitis C market is witnessing substantial growth, driven by the increasing demand for antiviral medications, diagnostic tools, and supportive care. Pharmaceutical companies are expanding their portfolios and collaborating with healthcare providers to ensure the availability of affordable and effective treatments. As the global healthcare community continues to address the challenges posed by hepatitis C, the future holds promise. Advances in research, increased access to healthcare, and ongoing awareness campaigns are likely to contribute to further reducing the prevalence of hepatitis C and improving outcomes for those affected.

Government Initiatives and Healthcare Policies is Driving the Global Hepatitis C Market

In recent years, the global healthcare landscape has witnessed a significant transformation, with governments around the world taking proactive measures to address and combat various health challenges. One such area where substantial progress has been made is in the management of Hepatitis C. Governments across the globe have initiated comprehensive healthcare policies and programs, fostering a conducive environment for the development and growth of the global Hepatitis C market. Governments have been actively involved in launching widespread screening and awareness programs to identify and educate individuals at risk of Hepatitis C. Early detection is crucial for timely intervention and treatment, reducing the overall burden on healthcare systems.

Many governments have worked towards improving access to affordable Hepatitis C treatment. Negotiating with pharmaceutical companies, implementing generic drug policies, and subsidizing treatment costs are some strategies employed to ensure that a larger portion of the population can afford effective medications. Numerous countries have developed and implemented national hepatitis strategies to coordinate efforts in preventing, diagnosing, and treating Hepatitis C. These strategies often involve collaboration between healthcare professionals, public health organizations, and policymakers to streamline the delivery of healthcare services. The adoption of universal health coverage policies has played a pivotal role in ensuring that individuals infected with Hepatitis C have access to essential healthcare services without facing financial barriers. These policies contribute to the broader goal of achieving health equity.

Governments are increasingly engaging in partnerships with private healthcare providers and pharmaceutical companies to enhance the reach and efficiency of Hepatitis C treatment programs. Such collaborations facilitate the development of innovative solutions and the optimization of existing resources. Regulatory reforms are critical in creating an environment conducive to the development and approval of new Hepatitis C treatments. Governments are working towards expediting the regulatory processes, ensuring that safe and effective medications reach the market sooner.

Key Market Challenges

Challenges in Diagnosing and Linking to Care

One of the primary challenges in combating Hepatitis C is the underdiagnosis of the virus. Many individuals infected with HCV are unaware of their condition due to the asymptomatic nature of the early stages of the disease. Lack of awareness, limited access to healthcare facilities, and the stigma associated with the disease contribute to delayed or missed diagnoses. Conventional diagnostic methods such as antibody tests may not be sufficient for accurate detection. Molecular tests, like polymerase chain reaction (PCR), are more sensitive and specific but may not be readily available in resource-limited settings. The absence of routine screening for Hepatitis C in some regions also compounds the problem, leading to late-stage diagnoses when the disease has already progressed.

Cost of Treatment

The exorbitant cost of hepatitis C treatment presents a formidable obstacle to access, particularly in regions where healthcare resources are scarce and insurance coverage is inadequate. Despite the existence of generic versions of direct-acting antivirals (DAAs), affordability remains a pervasive issue for numerous patients and healthcare systems alike. This financial barrier perpetuates disparities in treatment access and outcomes, exacerbating the burden of hepatitis C-related morbidity and mortality in vulnerable populations.

In response to this challenge, various strategies have been proposed to enhance affordability and promote equitable access to treatment. One approach involves advocating for lower prices through negotiation with pharmaceutical manufacturers, urging them to reconsider pricing models to make hepatitis C medications more accessible to those in need. Implementing tiered pricing schemes based on countries' income levels or healthcare expenditures could help ensure that treatment costs are proportionate to each nation's economic capacity. Expanding access to generic drugs through voluntary licensing agreements could serve as a mechanism to increase affordability and widen treatment availability. By granting licenses to generic manufacturers to produce and distribute low-cost versions of patented medications, healthcare systems can leverage competition to drive down prices and improve accessibility for underserved populations.

Key Market Trends

Technological Advancements

The global healthcare landscape is witnessing a remarkable transformation driven by technological advancements, and the field of hepatitis C treatment is no exception. Hepatitis C, a viral infection affecting the liver, has been a significant public health concern worldwide. However, the relentless pursuit of innovation in medical technologies has paved the way for groundbreaking developments in the diagnosis, treatment, and management of hepatitis C. One of the key areas where technological advancements have made a profound impact is in the diagnosis of hepatitis C. Traditional diagnostic methods were often time-consuming and less accurate. However, the advent of advanced diagnostic tools, such as nucleic acid tests (NAT) and polymerase chain reaction (PCR), has revolutionized the detection of hepatitis C virus (HCV) with greater sensitivity and specificity.

Point-of-care testing (POCT) devices have also emerged, enabling rapid and on-the-spot diagnosis, especially in resource-limited settings. These technological innovations not only enhance early detection but also facilitate prompt initiation of treatment, ultimately improving patient outcomes. The landscape of hepatitis C treatment has undergone a paradigm shift with the development of direct-acting antiviral agents (DAAs). These drugs target specific steps in the HCV replication process, leading to higher cure rates and fewer side effects compared to traditional interferon-based therapies. The use of artificial intelligence (AI) and machine learning in drug discovery and development has accelerated the identification of novel compounds and potential drug candidates. This has significantly reduced the time and resources required for the development of new antiviral therapies.

Telemedicine has become an integral part of healthcare delivery, providing remote access to medical services and monitoring for patients with chronic conditions like hepatitis C. Technological platforms enable healthcare professionals to remotely assess patient progress, offer consultations, and monitor treatment adherence. Mobile applications and wearable devices contribute to patient engagement by providing real-time data on vital signs, medication adherence, and overall health status. These tools empower patients to actively participate in their treatment plans and allow healthcare providers to intervene promptly if issues arise. The integration of data analytics and population health management tools has enhanced our understanding of hepatitis C epidemiology and outcomes. Health systems and organizations can now leverage big data to identify high-risk populations, track disease trends, and allocate resources more efficiently. Predictive analytics also play a crucial role in forecasting disease prevalence and anticipating healthcare needs. This proactive approach aids in the development of targeted interventions and public health campaigns, ultimately contributing to the global effort to eliminate hepatitis C.

Segmental Insights

Type Insights

Based on the category of type, Chronic Hepatitis C emerged as the dominant player in the global market for Hepatitis C in 2023. Several factors contribute to the dominance of Chronic Hepatitis C in the global hepatitis C market. One key element is the often-asymptomatic nature of the infection during its early stages, leading to delayed diagnosis. Individuals infected with the hepatitis C virus may remain unaware of their condition for years, allowing the virus to persist and cause chronic inflammation of the liver.

Unlike other forms of hepatitis, Chronic Hepatitis C can progress silently over several years, gradually damaging the liver without noticeable symptoms. By the time symptoms manifest, substantial liver damage may have occurred. This delayed detection poses a significant challenge in the effective management and treatment of the disease. The dominance of Chronic Hepatitis C has profound implications for global healthcare systems. The increasing prevalence of the infection places a substantial burden on healthcare resources, ranging from diagnostic tools to treatment options. The economic impact is significant, as the costs associated with managing advanced liver diseases and related complications escalate.

Treatment Insights

The Antiviral Drugs segment is projected to experience rapid growth during the forecast period. The journey of antiviral drugs in treating hepatitis C began with interferon-based therapies. However, these treatments were often associated with adverse effects and limited efficacy. The landscape changed dramatically with the introduction of direct-acting antivirals (DAAs). DAAs revolutionized hepatitis C treatment by targeting specific steps in the virus's life cycle, leading to higher cure rates and fewer side effects. Antiviral drugs, particularly DAAs, have demonstrated superior efficacy in eradicating the hepatitis C virus (HCV) from the body. These drugs inhibit the replication of the virus, allowing for a more targeted and effective treatment approach. The tolerability of antiviral drugs has improved significantly compared to earlier therapies, resulting in increased patient compliance and satisfaction.

Regional Insights

North America emerged as the dominant region in the global Hepatitis C market in 2023, holding the largest market share in terms of value. North America has witnessed a high prevalence of hepatitis C infections, driving the demand for effective treatments and medications. The region's robust healthcare infrastructure and awareness programs have played a crucial role in identifying and addressing hepatitis C cases promptly.

The United States, in particular, has been at the forefront of research and development in the pharmaceutical industry. Major pharmaceutical companies based in North America have invested heavily in the development of innovative drugs for hepatitis C treatment. Breakthroughs in antiviral therapies and direct-acting antivirals (DAAs) have significantly improved the efficacy of hepatitis C treatments.

Key Market Players

Pfizer Inc.

GlaxoSmithKline plc

Novartis AG

Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Boehringer Ingelheim International GmbH

Bayer AG

Merck & Co., Inc.

F. Hoffmann-La Roche AG

Bristol-Myers Squibb Company B

Report Scope:

In this report, the Global Hepatitis C Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis C Market, By Type:

    Acute Hepatitis C Chronic Hepatitis C Other

Hepatitis C Market, By Treatment:

    Antiviral Drugs Vaccine Immune Modulator Drugs Surgery Others

Hepatitis C Market, By Diagnosis:

    Liver Biopsy Blood Tests Imaging Tests Others

Hepatitis C Market, By Route of Administration:

    Oral Parenteral Others

Hepatitis C Market, By Distribution Channel:

    Hospital Pharmacy Retail Pharmacy Online Pharmacy Others

Hepatitis C Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Hepatitis C Market.

Available Customizations:

Global Hepatitis C market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis C Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Acute Hepatitis C, Chronic Hepatitis C, Others)
    • 5.2.2. By Treatment (Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Others)
    • 5.2.3. By Diagnosis (Liver Biopsy, Blood Tests, Imaging Tests, Others)
    • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.5. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
    • 5.2.6. By Company (2023)
    • 5.2.7. By Region
  • 5.3. Market Map

6. North America Hepatitis C Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Diagnosis
    • 6.2.4. By Route of Administration
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis C Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Diagnosis
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Mexico Hepatitis C Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Diagnosis
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Canada Hepatitis C Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Diagnosis
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Distribution Channel

7. Europe Hepatitis C Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Diagnosis
    • 7.2.4. By Route of Administration
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Hepatitis C Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Diagnosis
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Germany Hepatitis C Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Diagnosis
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Hepatitis C Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Diagnosis
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Hepatitis C Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Diagnosis
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Hepatitis C Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Diagnosis
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Hepatitis C Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Diagnosis
    • 8.2.4. By Route of Administration
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hepatitis C Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Diagnosis
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Hepatitis C Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Diagnosis
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. South Korea Hepatitis C Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Diagnosis
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Japan Hepatitis C Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Diagnosis
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Hepatitis C Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Diagnosis
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Distribution Channel

9. South America Hepatitis C Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By Route of Administration
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hepatitis C Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Diagnosis
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. Argentina Hepatitis C Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Diagnosis
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Colombia Hepatitis C Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Diagnosis
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Hepatitis C Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Diagnosis
    • 10.2.4. By Route of Administration
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Hepatitis C Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Diagnosis
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Saudi Arabia Hepatitis C Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Diagnosis
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. UAE Hepatitis C Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Diagnosis
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Pfizer Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. GlaxoSmithKline plc
  • 14.3. Novartis AG
  • 14.4. Mylan N.V.
  • 14.5. Teva Pharmaceutical Industries Ltd.
  • 14.6. Boehringer Ingelheim International GmbH
  • 14.7. Bayer AG
  • 14.8. Merck & Co., Inc.
  • 14.9. F. Hoffmann-La Roche AG
  • 14.10. Bristol-Myers Squibb Company

15. Strategic Recommendations

16. About Us & Disclaimer